Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + atezolizumab versus placebo + atezolizumab in first-line PD-L1-selected advanced non-small cell lung cancer
NL-OMON59617Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jun 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59617.